Cannabinoids, the active compounds found in the cannabis plant, have garnered significant attention for their potential therapeutic applications in neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and multiple sclerosis (MS). These diseases are characterized by progressive neuronal loss, leading to cognitive and motor impairments. The endocannabinoid system (ECS), comprising cannabinoid receptors (CB1 and CB2), endogenous ligands, and metabolic enzymes, plays a crucial role in modulating neuroinflammation, oxidative stress, and neuroprotection, making it a promising target for therapeutic intervention.
Alzheimer's Disease (AD): AD is marked by the accumulation of β-amyloid plaques and tau protein tangles, leading to neuroinflammation and x products can cannon 308 neuronal death.